Data gathered: July 12
Alternative Data for Biogen
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 175 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 128,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | 48 | Sign up | Sign up | Sign up |
| Patents | 78 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 120 | Sign up | Sign up | Sign up |
| Facebook Followers | 21,120 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 16 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 18,625 | Sign up | Sign up | Sign up |
| Twitter Followers | 44,940 | Sign up | Sign up | Sign up |
| Twitter Mentions | 58 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 10,400 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 34 | Sign up | Sign up | Sign up |
| Linkedin Employees | 7,642 | Sign up | Sign up | Sign up |
About Biogen
Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.
| Price | $134.21 |
| Target Price | Sign up |
| Volume | 1,140,000 |
| Market Cap | $19.8B |
| Year Range | $113.38 - $176.93 |
| Dividend Yield | 0% |
| PE Ratio | 13.37 |
| Analyst Rating | 33% buy |
| Earnings Date | July 31 '25 |
| Industry | Biotechnology |
In the news
 |
RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PTJuly 10 - Biztoc.com |
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) CongressJuly 10 - Financial Post |
|
 |
Principal Financial Group Inc. Boosts Stake in Biogen Inc. (NASDAQ:BIIB)July 10 - ETF Daily News |
 |
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) CongressJuly 9 - Yahoo |
Biogen : Preliminary Q2 2025 Acquired IPRD & Licensing IncomeJuly 7 - Finnhub |
|
Biogen estimated charge to impact eps by ($0.26) per share for q2July 7 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 2.43B | 629M | 1.8B | 241M | 554M | 3.020 |
| Q4 '24 | 2.45B | 584M | 1.87B | 267M | 536M | 3.440 |
| Q3 '24 | 2.47B | 639M | 1.83B | 389M | 694M | 4.080 |
| Q2 '24 | 2.46B | 546M | 1.92B | 584M | 919M | 5.280 |
| Q1 '24 | 2.29B | 542M | 1.75B | 393M | 682M | 3.670 |
Insider Transactions View All
| Singhal Priya filed to sell 5,427 shares at $126.3. May 20 '25 |
| DORSA CAROLINE filed to buy 27,842 shares at $122.7. May 5 '25 |
| SHERWIN STEPHEN A filed to sell 11,318 shares at $150. March 10 '25 |
| Singhal Priya filed to sell 5,426 shares at $157.2. December 9 '24 |
| Singhal Priya filed to sell 5,316 shares at $204.2. September 5 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Rob Bresnahan |
Jun 10, 25 | Buy | $1K - $15K |
| Rob Bresnahan |
Mar 28, 25 | Buy | $1K - $15K |
| Ro Khanna |
Dec 6, 24 | Buy | $1K - $15K |
Read more about Biogen (BIIB) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Biogen?
The Market Cap of Biogen is $19.8B.
What is Biogen's PE Ratio?
As of today, Biogen's PE (Price to Earnings) ratio is 13.37.
When does Biogen report earnings?
Biogen will report its next earnings on July 31 '25.
What is the current stock price of Biogen?
Currently, the price of one share of Biogen stock is $134.21.
How can I analyze the BIIB stock price chart for investment decisions?
The BIIB stock price chart above provides a comprehensive visual representation of Biogen's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Biogen shares. Our platform offers an up-to-date BIIB stock price chart, along with technical data analysis and alternative data insights.
Does BIIB offer dividends to its shareholders?
As of our latest update, Biogen (BIIB) does not offer dividends to its shareholders. Investors interested in Biogen should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Biogen?
Some of the similar stocks of Biogen are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.